OR7C2

Across TCGA pan-cancer cohorts, OR7C2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR7C2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OR7C2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR7C2 expression acts as an unfavorable survival marker.

UCEC, LGG, and BLCA are the cancer types where OR7C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
LGG	OS	Median	All	0.306	0.811	.007	6	view →
BLCA	OS	Median	III,IV	0.117	0.684	<.001	6	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR7C2–UCEC (OS)

Open the UCEC breakdown →